Antiparasitic Uses

Search “artemisinin parasites” and you will find a protocol for almost anything — Toxoplasma, Babesia, Lyme co-infections, intestinal worms, “parasite cleanses.” Underneath that noise there is a real scientific literature, and it is much narrower than the marketing.

Here is the honest shape of it. Artemisinin derivatives have genuine, human-tested activity against schistosomiasis, where they are used as drugs alongside or instead of praziquantel in specific circumstances. Everything else — Toxoplasma, Babesia, Leishmania, liver flukes, coccidia — is cell-culture and animal work, some of it good, none of it a human treatment. And the plant’s common name is actively misleading: sweet wormwood is not the traditional deworming herb. That was a different Artemisia entirely.

One more thing before we start. Every use below that has any human evidence is a use of a purified drug, at a measured dose, under supervision — and deploying artemisinins broadly against worms in malaria-endemic regions carries its own resistance cost, which is why the practice is contested even among the researchers who study it.

Table of Contents

1. What Is Real and What Is Hoped For
2. Schistosomiasis: The Strongest Case
3. Liver Flukes and Other Trematodes
4. Toxoplasma gondii
5. Babesia and the Veterinary Evidence
6. Leishmania
7. The “Wormwood” Name Trap
8. Why Plants Against Parasites Is Harder Than It Looks
9. Parasite Cleanses and What They Cost You
10. Cautions
11. Key Research Papers
12. Connections

What Is Real and What Is Hoped For

Schistosomiasis: The Strongest Case

Schistosomiasis — bilharzia — is a blood-fluke infection acquired from freshwater snails, affecting well over 200 million people, mostly in sub-Saharan Africa. The standard treatment is praziquantel, a single oral dose, cheap and effective. Praziquantel has one well-known blind spot: it works on adult worms but poorly on the immature schistosomula that circulate for the first weeks after infection.

Artemisinins have the mirror-image profile. Artemether and artesunate are most active against the juvenile stages praziquantel misses. That complementarity is why the combination has been studied seriously since the 1990s, particularly in China against Schistosoma japonicum, and later in Africa against S. mansoni and S. haematobium.

Two systematic reviews summarise the human evidence:

• A 2011 systematic review and meta-analysis in Parasites & Vectors pooled trials of praziquantel and artemisinin derivatives for treatment and prevention of human schistosomiasis, and found artemisinin derivatives effective for prevention (chemoprophylaxis in exposed populations) and the combination superior to either drug alone for cure.
• A 2012 systematic review and meta-analysis in PLoS One reached compatible conclusions across S. japonicum, S. mansoni and S. haematobium, with the combination outperforming praziquantel monotherapy in cure rate.

So this is real. But three qualifications matter more than the headline.

First, this is the drug, not the tea. These trials used artesunate or artemether tablets at defined milligram doses, usually in repeated regimens over weeks, and usually with praziquantel. Nobody has shown that a herbal infusion reproduces it. The one large trial that claimed Artemisia tea beat praziquantel for schistosomiasis — published in Phytomedicine in 2018 — was retracted in 2020, along with its malaria companion paper.

Second, the trial base is heterogeneous. Doses, schedules, species and endpoints varied widely, and much of the early work is Chinese-language and from a single national programme. Meta-analyses of heterogeneous trials give you a direction, not a precise effect size.

Third — and this is the argument that has kept artemisinins out of routine schistosomiasis control — using them at scale in Africa means dosing millions of people who also carry malaria parasites. That is population-level artemisinin exposure outside of malaria treatment, which is exactly the pressure that selects for artemisinin-resistant Plasmodium. Researchers in this field, including the ones who established the schistosomiasis activity, have flagged this trade-off explicitly. It is a genuine dilemma between two diseases, not a reason to dismiss the data.

Liver Flukes and Other Trematodes

The same logic that makes artemisinins work against schistosomes — they are trematodes, they consume blood, they are rich in heme — predicts activity against other blood-feeding flukes. Laboratory work supports this.

In rodent models, artesunate and artemether showed activity against Clonorchis sinensis (the Chinese liver fluke) and Opisthorchis viverrini (the Southeast Asian liver fluke) — both major causes of cholangiocarcinoma in endemic regions. Reviews of artemisinins and synthetic trioxolanes in helminth infection cover activity against Fasciola hepatica and several other trematodes as well.

What does not yet exist is a convincing body of human trials. The current human treatment for these flukes remains praziquantel (or triclabendazole for Fasciola). Artemisinins here are an interesting second line in research, not an option to self-select.

Notice the pattern across this whole article: artemisinin’s activity tracks organisms that eat blood or otherwise concentrate free iron. That is not a coincidence, it is the mechanism. It is also why the claims that stray furthest from blood-feeding parasites — intestinal worms, systemic “candida,” unspecified “parasites” — have the least support.

Toxoplasma gondii

Toxoplasma gondii is an intracellular protozoan related to Plasmodium, so activity is mechanistically plausible, and it has been demonstrated repeatedly in the laboratory.

Artemisinin derivatives inhibit T. gondii in vitro at multiple steps in the lytic cycle — not just replication but invasion and egress. Medicinal-chemistry groups have built thiazole, oxadiazole and carboxamide derivatives of artemisinin that are highly selective and potent against the parasite in cell culture, with selectivity indices good enough to justify continued development. More recent work has combined artemisinin with ferroptosis inducers and tested artemisone and artemiside in experimentally infected mice.

What none of this includes is a human trial. Toxoplasmosis in an immunocompetent person usually needs no treatment; in pregnancy, in a newborn, or in someone immunosuppressed, it needs proven therapy — pyrimethamine plus sulfadiazine with leucovorin, or the alternatives a specialist chooses. Substituting an untested herb in any of those situations risks blindness or brain damage in someone who could have been treated.

There is also a specific, unresolved obstacle: no drug reliably clears the tissue cysts of chronic toxoplasmosis, and artemisinin has not been shown to be an exception. Claims that an artemisinin supplement can “clear latent toxo” run ahead of anything demonstrated even in mice.

Babesia and the Veterinary Evidence

Babesia is a tick-borne intraerythrocytic parasite — a genuine malaria analogue that lives in red blood cells and digests haemoglobin. It causes human babesiosis (often alongside Lyme disease) and serious veterinary disease in dogs and cattle.

The laboratory story is consistent. Artesunate showed activity against Babesia in vitro and in rodent models in a 2010 study, and later work examined artesunate-based combinations against B. bovis in vitro and B. microti in mice. In veterinary practice, combinations including artesunate have been used to treat dogs naturally infected with Babesia gibsoni, with published clinical efficacy and safety data.

Human babesiosis is treated with atovaquone plus azithromycin, or clindamycin plus quinine for severe disease, with exchange transfusion in life-threatening cases. Artemisinin is not part of any guideline. It appears constantly in tick-borne-illness supplement protocols anyway — often as “artemisinin” or “sweet wormwood” capsules taken for months. If you are in that situation: babesiosis is diagnosable with a blood smear and PCR and is treatable with drugs that have human evidence. Get the diagnosis confirmed and treated properly, then discuss anything else with the clinician managing it.

Leishmania

Leishmania species cause cutaneous, mucocutaneous and visceral leishmaniasis — the visceral form (kala-azar) being fatal untreated. Existing treatments are genuinely bad: toxic, expensive, injectable, and increasingly resistance-limited. So the search for alternatives is well motivated.

Artemisinin and fluorinated artemisinin derivatives show antileishmanial activity in vitro against L. donovani promastigotes and amastigotes; artemisinin induced apoptosis-like death in L. major and reduced lesion size in BALB/c mice; lipid-based and nanoparticle formulations have been developed to improve delivery. A 2024 review in Phytomedicine groups artemisinin with other natural endoperoxides as promising anti-leishmanials.

All of it is preclinical. “Promising anti-leishmanial” in a review title means promising in a dish and in a mouse. There is no human leishmaniasis trial of artemisinin to report, positive or negative.

The “Wormwood” Name Trap

This is the most consequential confusion in the whole subject, and it explains why sweet wormwood ends up in products that have nothing to do with its actual pharmacology.

English lumps at least three unrelated medicinal plants under names containing “wormwood” or “wormseed”:

• Artemisia annua — sweet wormwood, sweet Annie, qinghao. The artemisinin plant. Historically used in China for fevers, not for worms. This is the subject of this article.
• Artemisia absinthium — common wormwood. The bitter perennial of absinthe fame, containing thujone and intensely bitter sesquiterpene lactones. This is the plant with the European vermifuge reputation, and it is a different chemistry entirely — no artemisinin. See our Wormwood page.
• Artemisia cina and relatives — wormseed, santonica. The historical source of santonin, an anthelmintic that was a mainstream pharmaceutical for roundworm through the nineteenth and early twentieth centuries and was abandoned for toxicity (including visual disturbances and convulsions) once safer drugs arrived.

So when a “parasite cleanse” formula lists “wormwood,” it may contain any of these — and the traditional deworming rationale, such as it is, belongs to the ones that do not contain artemisinin. Conversely, when a product advertises artemisinin content, it is trading on the malaria literature, which is about a blood protozoan and has nothing to do with intestinal worms.

Mugwort (A. vulgaris) adds a fourth plant to the pile. It is the moxibustion herb and a major pollen allergen; it is not the malaria plant either.

Why Plants Against Parasites Is Harder Than It Looks

Three structural reasons the in-vitro results in this article do not convert into home remedies:

1. The concentrations do not transfer. A cell-culture experiment establishes an IC₅₀ in a dish. Reaching that concentration in the tissue where the parasite lives — brain cysts, bile ducts, macrophages, red cells — is a separate and much harder problem, and artemisinin’s short half-life and self-induced metabolism make it particularly unforgiving.
2. Whole-plant material is a variable dose. Artemisinin content in dried leaf varies severalfold with cultivar, climate and harvest. A protocol specifying “500 mg sweet wormwood twice daily” specifies almost nothing about how much active compound is delivered. The forms and dosing article goes through this in detail.
3. Resistance is a shared resource problem. Every non-malarial use of an artemisinin in a malaria-endemic setting adds selection pressure on Plasmodium. That is the explicit reason artemisinins have not been rolled out for schistosomiasis control at scale despite the supporting trials.

Parasite Cleanses and What They Cost You

Multi-week “parasite cleanse” protocols — typically wormwood, black walnut hull and clove, sometimes with added artemisinin — are sold on the premise that most people harbour undiagnosed parasites causing fatigue, bloating and brain fog. There is no evidence for that premise in populations with modern sanitation, and no evidence that the protocols eliminate any specific organism.

The cost is not only money.

• Delay. The symptoms that send people to cleanses — chronic fatigue, abdominal pain, unexplained weight change — overlap with coeliac disease, inflammatory bowel disease, thyroid disease, anaemia and cancer. Weeks spent on a cleanse are weeks not spent getting a diagnosis.
• Missing a real, treatable parasite. If you genuinely have giardiasis, strongyloidiasis, amoebiasis or schistosomiasis, there is a specific stool test, serology or PCR for it, and a specific drug that cures it. Strongyloidiasis in particular can become fatal if someone is later given corticosteroids — it is worth diagnosing properly.
• Real toxicity. Thujone-containing wormwood at cleanse doses is neurotoxic; artemisinin supplements have been linked to cholestatic liver injury in case reports.

If you have a specific exposure — freshwater swimming in an endemic region, undercooked freshwater fish, a tick bite with fever, travel diarrhoea that never resolved — say so to a clinician and name it. That is a testable question with an answer.

Cautions

• Do not self-treat a suspected parasitic infection. Nearly every parasite in this article has a proven, specific drug. Diagnosis is what selects it.
• Pregnancy. Avoid A. annua and artemisinin supplements entirely — artemisinins are embryotoxic in early-pregnancy animal studies, and Artemisia species carry a traditional emmenagogue reputation. (Treating malaria in pregnancy with ACT is a different, clinician-supervised situation.)
• Asteraceae allergy. Artemisia is a major aeroallergen genus with well-documented cross-reactivity to mugwort, sage and ragweed. If you react to that family, avoid.
• Liver. Case reports link artemisinin supplements to cholestatic liver injury, including one case with intrahepatic ductopenia. Long multi-month “protocols” are exactly the pattern at issue.
• Drug interactions. Artemisinin induces CYP2B6 and CYP3A4 and autoinduces its own clearance, while whole-leaf extract can inhibit the same enzymes. Either direction can shift the level of a prescription drug — and people on tick-borne-illness protocols are often taking several.
• Never use artemisinin products as malaria prophylaxis. See the malaria article: travellers who did this developed imported falciparum malaria.

Key Research Papers

Every PMID below was verified live against NCBI E-utilities — first author, title, journal and year all matched before publication. Each entry states whether the finding is human, animal or cell-culture.

Schistosomiasis (human evidence)

1. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta-analysis. Parasites & Vectors. 2011;4:201. Human trials, pooled.
2. Pérez del Villar L, Burguillo FJ, López-Abán J, Muro A. Systematic review and meta-analysis of artemisinin based therapies for the treatment and prevention of schistosomiasis. PLoS One. 2012;7(9):e45867. Human trials, pooled.
3. Utzinger J, Xiao SH, N’Goran EK, Bergquist R, Tanner M. Artemisinins for schistosomiasis and beyond. Current Opinion in Investigational Drugs. 2007;8(2):105–116. Includes the resistance trade-off argument.
4. RETRACTED. Munyangi J, Cornet-Vernet L, Idumbo M, et al. Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial. Phytomedicine. 2018;51:233–240. Retraction notice: Phytomedicine. 2020;78:153303. Cannot be used as evidence.
5. Argemi X, Hansmann Y, Gaudart J, Gillibert A. Comment on “Effect of Artemisia annua and Artemisia afra tea infusions on schistosomiasis in a large clinical trial.” Phytomedicine. 2019;62:152804.

Helminths and liver flukes (animal)

1. Keiser J, Xiao SH, Tanner M, Utzinger J. Effect of artesunate and artemether against Clonorchis sinensis and Opisthorchis viverrini in rodent models. International Journal of Antimicrobial Agents. 2006;28(4):370–373. Rodent.
2. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Current Opinion in Infectious Diseases. 2007;20(6):605–612.
3. Lam NS, Long X, Su XZ, Lu F. Artemisinin and its derivatives in treating helminthic infections beyond schistosomiasis. Pharmacological Research. 2018;133:77–100.

Protozoa other than malaria (cell culture and animal)

1. Loo CS, Lam NS, Yu D, Su XZ, Lu F. Artemisinin and its derivatives in treating protozoan infections beyond malaria. Pharmacological Research. 2017;117:192–217. The single best overview of this whole field.
2. D’Angelo JG, Bordón C, Posner GH, Yolken R, Jones-Brando L. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. Journal of Antimicrobial Chemotherapy. 2009;63(1):146–150. Cell culture.
3. Hencken CP, Jones-Brando L, Bordón C, et al. Thiazole, oxadiazole, and carboxamide derivatives of artemisinin are highly selective and potent inhibitors of Toxoplasma gondii. Journal of Medicinal Chemistry. 2010;53(9):3594–3601. Cell culture.
4. Goo YK, Terkawi MA, Jia H, et al. Artesunate, a potential drug for treatment of Babesia infection. Parasitology International. 2010;59(3):481–486. In vitro and rodent.
5. Carvalho LJM, Tuvshintulga B, Nugraha AB, Sivakumar T, Yokoyama N. Activities of artesunate-based combinations and tafenoquine against Babesia bovis in vitro and Babesia microti in vivo. Parasites & Vectors. 2020;13(1):362. In vitro and rodent.
6. Karasová M, Tóthová C, Grelová S, et al. Clinical efficacy and safety of Malarone, azithromycin and artesunate combination for treatment of Babesia gibsoni in naturally infected dogs. Animals. 2022;12(6). Veterinary.
7. Ghaffarifar F, Esavand Heydari F, Dalimi A, Hassan ZM, Delavari M, Mikaeiloo H. Evaluation of apoptotic and antileishmanial activities of artemisinin on promastigotes and BALB/c mice infected with Leishmania major. Iranian Journal of Parasitology. 2015;10(2):258–267. Cell culture and mouse.
8. Chollet C, Crousse B, Bories C, Bonnet-Delpon D, Loiseau PM. In vitro antileishmanial activity of fluoro-artemisinin derivatives against Leishmania donovani. Biomedicine & Pharmacotherapy. 2008;62(7):462–465. Cell culture.
9. Sarkar D, Ghosh S, Chattopadhyay A, et al. Natural endoperoxides as promising anti-leishmanials. Phytomedicine. 2024;129:155640. Review of preclinical work.

Context: the plant, its chemistry and its safety

1. Feng X, Cao S, Qiu F, Zhang B. Traditional application and modern pharmacological research of Artemisia annua L. Pharmacology & Therapeutics. 2020;216:107650.
2. Hussain M, Thakur RK, Khazir J, et al. Traditional uses, phytochemistry, pharmacology, and toxicology of the genus Artemisia L. (Asteraceae): a high-value medicinal plant. Current Topics in Medicinal Chemistry. 2024;24(4):301–342. Useful for sorting out which Artemisia is which.
3. Ruperti-Repilado FJ, Haefliger S, Rehm S, et al. Danger of herbal tea: a case of acute cholestatic hepatitis due to Artemisia annua tea. Frontiers in Medicine. 2019;6:221. Human case report.
4. Katial RK, Lin FL, Stafford WW, Ledoux RA, Westley CR, Weber RW. Mugwort and sage (Artemisia) pollen cross-reactivity: ELISA inhibition and immunoblot evaluation. Annals of Allergy, Asthma & Immunology. 1997;79(4):340–346.

Live PubMed Searches

1. Artesunate and praziquantel in schistosomiasis
2. Artemether against juvenile schistosomes
3. Artemisinin and Toxoplasma gondii
4. Artesunate and Babesia
5. Artemisinin and Leishmania
6. Artemisinin and liver flukes
7. Santonin and Artemisia cina
8. Artemisinin beyond malaria

Connections

• All Herbs
• Artemisia annua Benefits — the hub
• Artemisia annua (Sweet Wormwood)
• Artemisinin and Malaria — the one indication with human-scale evidence
• Forms, Dosing, and the Herb vs Drug Question
• Inflammation and Immune
• Malaria
• Wormwood (Artemisia absinthium) — the bitter vermifuge cousin, thujone not artemisinin
• Mugwort (Artemisia vulgaris) — the third plant in the name confusion
• Andrographis

Back to Table of Contents